In a landmark deal for the biotechnology sector, our client ABC BioTech was acquired by global pharmaceutical leader MedGen for $240 million. The transaction represents a major milestone for the founders and demonstrates the strength of our strategic advisory in high-growth healthtech ventures. Partner Sarah Lin led the engagement from initial funding through to acquisition.
In a landmark deal for the biotechnology sector, our client ABC BioTech was acquired by global pharmaceutical leader MedGen for $240 million. The transaction represents a major milestone for the founders and demonstrates the strength of our strategic advisory in high-growth healthtech ventures. Partner Sarah Lin led the engagement from initial funding through to acquisition.
In a landmark deal for the biotechnology sector, our client ABC BioTech was acquired by global pharmaceutical leader MedGen for $240 million. The transaction represents a major milestone for the founders and demonstrates the strength of our strategic advisory in high-growth healthtech ventures. Partner Sarah Lin led the engagement from initial funding through to acquisition.
In a landmark deal for the biotechnology sector, our client ABC BioTech was acquired by global pharmaceutical leader MedGen for $240 million. The transaction represents a major milestone for the founders and demonstrates the strength of our strategic advisory in high-growth healthtech ventures. Partner Sarah Lin led the engagement from initial funding through to acquisition.
In a landmark deal for the biotechnology sector, our client ABC BioTech was acquired by global pharmaceutical leader MedGen for $240 million. The transaction represents a major milestone for the founders and demonstrates the strength of our strategic advisory in high-growth healthtech ventures. Partner Sarah Lin led the engagement from initial funding through to acquisition.
In a landmark deal for the biotechnology sector, our client ABC BioTech was acquired by global pharmaceutical leader MedGen for $240 million. The transaction represents a major milestone for the founders and demonstrates the strength of our strategic advisory in high-growth healthtech ventures. Partner Sarah Lin led the engagement from initial funding through to acquisition.
In a landmark deal for the biotechnology sector, our client ABC BioTech was acquired by global pharmaceutical leader MedGen for $240 million. The transaction represents a major milestone for the founders and demonstrates the strength of our strategic advisory in high-growth healthtech ventures. Partner Sarah Lin led the engagement from initial funding through to acquisition.
In a landmark deal for the biotechnology sector, our client ABC BioTech was acquired by global pharmaceutical leader MedGen for $240 million. The transaction represents a major milestone for the founders and demonstrates the strength of our strategic advisory in high-growth healthtech ventures. Partner Sarah Lin led the engagement from initial funding through to acquisition.
